Arms |
Assigned Interventions |
Experimental:ALX148
The Part 1 Dose Escalation: ALX148 infusions will be administered weekly or every two weeks.
|
Drug:ALX148 ALX148 |
Experimental:ALX148 + Pembrolizumab
The Part 2 Dose Escalation/Expansion: ALX148 infusions will be administered weekly or every two weeks in combination with pembrolizumab infusions.
|
Drug:Pembrolizumab Keytruda |
Experimental:ALX148 + Trastuzumab
The Part 2 Dose Escalation/Expansion: ALX148 infusions will be administered weekly or every two weeks in combination with trastuzumab infusions.
|
Drug:Trastuzumab Herceptin |
Experimental:ALX148 + Rituximab
The Part 2 Dose Escalation/Expansion: ALX148 infusions will be administered weekly or every two weeks in combination with rituximab infusions.
|
Drug:Rituximab Rituxan |
Experimental:ALX148 + Pembrolizumab + 5FU + Platinum
The Part 2 Dose Escalation: ALX148 infusions will be administered weekly or every two weeks in combination with pembrolizumab + 5FU + platinum infusions.
|
Drug:5-FU + Cisplatin Standard of care chemotherapy |
Experimental:ALX148 + Trastuzumab + Ramucirumab + Paclitaxel
The Part 2 Dose Escalation: ALX148 infusions will be administered weekly or every two weeks in combination with trastuzumab + ramucirumab + paclitaxel infusions.
|
Drug:Ramucirumab + Paclitaxel Standard of care chemotherapy |